Idera Pharmaceuticals, Inc.
Records under this name other than the patents Idera Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Back to Idera Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,853,177 | Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto Lapsed on the fee record Ended Oct 7, 2026 · High confidence | Lapsed on the fee record | Ended Oct 7, 2026 | High confidence |
| US 8,853,375 | Toll Like Receptor Modulators Lapsed on the fee record Ended Oct 7, 2026 · High confidence | Lapsed on the fee record | Ended Oct 7, 2026 | High confidence |
| US 10,066,230 | Immune Regulatory Oligonucleotide (IRO) Compounds to Modulate Toll-Like Receptor Based Immune Response Lapsed on the fee record Ended Sep 4, 2026 · Medium confidence | Lapsed on the fee record | Ended Sep 4, 2026 | Medium confidence |
| US 7,749,975 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends Term ended Term ended Aug 27, 2026 · From the USPTO record | Term ended | Term ended Aug 27, 2026 | From the USPTO record |
| US 10,041,076 | Immune Regulatory Oligonucleotide (IRO) Compounds to Modulate Toll-Like Receptor Based Immune Response Lapsed on the fee record Ended Aug 7, 2026 · Medium confidence | Lapsed on the fee record | Ended Aug 7, 2026 | Medium confidence |
| US 8,759,310 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 Lapsed on the fee record Ended Jun 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 24, 2026 | From the USPTO record |
| US 7,569,554 | Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents Term ended Term ended May 6, 2026 · From the USPTO record | Term ended | Term ended May 6, 2026 | From the USPTO record |
| US 11,224,611 | Immune modulation with TLR9 agonists for cancer treatment Lapsed on the fee record Ended Jan 18, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 18, 2026 | From the USPTO record |
| US 9,828,601 | Compositions for inhibiting checkpoint gene expression and uses thereof Lapsed on the fee record Ended Nov 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 28, 2025 | From the USPTO record |
| US 8,946,175 | Stabilized Immunomodulatory Oligonucleotides Term ended Ended no later than Oct 10, 2025 · Low confidence | Term ended | Ended no later than Oct 10, 2025 | Low confidence |